Suppr超能文献

相似文献

1
Estimated GFR Slope Across CKD Stages in Primary Hyperoxaluria Type 1.
Am J Kidney Dis. 2022 Sep;80(3):373-382. doi: 10.1053/j.ajkd.2022.01.428. Epub 2022 Mar 16.
3
CKD Progression and Mortality Among Men and Women: A Nationwide Study in Sweden.
Am J Kidney Dis. 2021 Aug;78(2):190-199.e1. doi: 10.1053/j.ajkd.2020.11.026. Epub 2021 Jan 9.
5
Progressive Decline in Estimated GFR in Patients With Sickle Cell Disease: An Observational Cohort Study.
Am J Kidney Dis. 2019 Jul;74(1):47-55. doi: 10.1053/j.ajkd.2018.12.027. Epub 2019 Feb 21.
6
End Points for Clinical Trials in Primary Hyperoxaluria.
Clin J Am Soc Nephrol. 2020 Jul 1;15(7):1056-1065. doi: 10.2215/CJN.13821119. Epub 2020 Mar 12.
7
Natural history of urine and plasma oxalate in children with primary hyperoxaluria type 1.
Pediatr Nephrol. 2024 Jan;39(1):141-148. doi: 10.1007/s00467-023-06074-x. Epub 2023 Jul 17.
8
Cancer Risk and Mortality in Patients With Kidney Disease: A Population-Based Cohort Study.
Am J Kidney Dis. 2022 Oct;80(4):436-448.e1. doi: 10.1053/j.ajkd.2022.02.020. Epub 2022 Apr 8.
9
Change in glomerular filtration rate over time in the Oxford Renal Cohort Study: observational study.
Br J Gen Pract. 2022 Mar 31;72(717):e261-e268. doi: 10.3399/BJGP.2021.0477. Print 2022 Apr.
10
Fast GFR decline and progression to CKD among primary care patients with preserved GFR.
Int Urol Nephrol. 2018 Mar;50(3):501-508. doi: 10.1007/s11255-018-1805-1. Epub 2018 Feb 5.

引用本文的文献

1
Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial.
Kidney Int Rep. 2024 Apr 26;9(7):2037-2046. doi: 10.1016/j.ekir.2024.04.048. eCollection 2024 Jul.
2
Primary Hyperoxaluria Type 1: Clinical, Paraclinical, and Evolutionary Aspects in Adults from One Nephrology Center.
Int J Nephrol. 2023 Jul 19;2023:2874414. doi: 10.1155/2023/2874414. eCollection 2023.

本文引用的文献

1
Natural History of Clinical, Laboratory, and Echocardiographic Parameters of a Primary Hyperoxaluria Cohort on Long Term Hemodialysis.
Front Med (Lausanne). 2021 Apr 9;8:592357. doi: 10.3389/fmed.2021.592357. eCollection 2021.
2
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
N Engl J Med. 2021 Apr 1;384(13):1216-1226. doi: 10.1056/NEJMoa2021712.
3
Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2.
Nephrol Dial Transplant. 2022 Apr 25;37(5):869-875. doi: 10.1093/ndt/gfab027.
4
Calcium oxalate crystal deposition in the kidney: identification, causes and consequences.
Urolithiasis. 2020 Oct;48(5):377-384. doi: 10.1007/s00240-020-01202-w. Epub 2020 Jul 27.
5
Pyridoxine Responsiveness in a Type 1 Primary Hyperoxaluria Patient With a Rare (Atypical) Gene Mutation.
Kidney Int Rep. 2020 Apr 13;5(6):955-958. doi: 10.1016/j.ekir.2020.04.004. eCollection 2020 Jun.
6
Plasma Oxalate as a Predictor of Kidney Function Decline in a Primary Hyperoxaluria Cohort.
Int J Mol Sci. 2020 May 20;21(10):3608. doi: 10.3390/ijms21103608.
7
End Points for Clinical Trials in Primary Hyperoxaluria.
Clin J Am Soc Nephrol. 2020 Jul 1;15(7):1056-1065. doi: 10.2215/CJN.13821119. Epub 2020 Mar 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验